Effects of CB2 and TRPV1 Stimulation on Osteoclast Overactivity Induced by Iron in Pediatric Inflammatory Bowel Disease

Abstract Background The reduction of bone mineral density and osteoporosis have high impacts on the health of patients with inflammatory bowel diseases (IBD). We have previously shown that a dysregulated iron metabolism occurs in IBD and leads to a decrease in circulating iron concentration and excessive intracellular sequestration of iron. Studies suggest that iron overload significantly affects the bone, accelerating osteoclast (OC) differentiation and activation, promoting bone resorption. Moreover, we demonstrated that iron overload causes OC overactivity. The cannabinoid receptor type 2 (CB2) and the transient receptor potential vanilloid type-1 (TRPV1) are potential therapeutic targets for bone diseases. The aim of this study was to evaluate the roles of CB2 and TRPV1 receptors and of iron in the development of osteoporosis in pediatric IBD. Methods We differentiated OCs from peripheral blood mononuclear cells of patients with IBD and healthy donors and evaluated CB2 and TRPV1 receptor expression; OC activity, and iron metabolism by Western blot, TRAP assays, bone resorption assays, and iron assays. Moreover, we analyzed the effects of the pharmacological modulation of CB2 and TRPV1 receptors on OC activity and on the iron metabolism. Results We confirmed the well-known roles of CB2 and TRPV1 receptors in bone metabolism and suggested that their stimulation can reduce the OC overactivity induced by iron, providing new insights into the pathogenesis of pediatric IBD-related bone resorption. Conclusions Stimulation of CB2 and TRPV1 could reduce IBD-related osteoporosis due to their direct effects on OC activity and to modulating the iron metabolism.

[1]  Zizhen Zhang,et al.  Gut-innervating TRPV1+ Neurons Drive Chronic Visceral Pain via Microglial P2Y12 Receptor , 2021, Cellular and molecular gastroenterology and hepatology.

[2]  V. Rizzo,et al.  Cannabis and Its Potential Protective Role Against Inflammatory Bowel Disease: A Scoping Review , 2021, Cureus.

[3]  Paweł Kuźnicki,et al.  Emerging Comorbidities in Inflammatory Bowel Disease: Eating Disorders, Alcohol and Narcotics Misuse , 2021, Journal of clinical medicine.

[4]  A. Swaminath,et al.  Inflammatory Bowel Disease and Cannabis: A Practical Approach for Clinicians , 2021, Advances in Therapy.

[5]  E. Pac-Kożuchowska,et al.  Interleukin 6: biological significance and role in inflammatory bowel diseases. , 2021, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[6]  N. Chattipakorn,et al.  Silencing of lipocalin‐2 improves cardiomyocyte viability under iron overload conditions via decreasing mitochondrial dysfunction and apoptosis , 2020, Journal of cellular physiology.

[7]  S. Stojkovic,et al.  Hepcidin Is a Reliable Marker of Iron Deficiency Anemia in Newly Diagnosed Patients with Inflammatory Bowel Disease , 2020, Disease markers.

[8]  C. Andrews,et al.  Cannabis in Gastroenterology: Watch Your Head! A Review of Use in Inflammatory Bowel Disease, Functional Gut Disorders, and Gut-Related Adverse Effects , 2020, Current Treatment Options in Gastroenterology.

[9]  A. Galli,et al.  Biomarkers of Inflammation in Inflammatory Bowel Disease: How Long before Abandoning Single-Marker Approaches? , 2020, Digestive Diseases.

[10]  A. Di Paola,et al.  The Role of Cannabinoid Receptor Type 2 in the Bone Loss Associated With Pediatric Celiac Disease , 2020, Journal of pediatric gastroenterology and nutrition.

[11]  H. Ishikawa,et al.  Serum hepcidin level, iron metabolism and osteoporosis in patients with rheumatoid arthritis , 2020, Scientific Reports.

[12]  M. Muckenthaler,et al.  Disruption of the hepcidin/ferroportin regulatory circuitry causes low axial bone mass in mice. , 2020, Bone.

[13]  Margaux J. Barnes,et al.  Relations between disease status and body composition in pediatric inflammatory bowel disease , 2020, European Journal of Pediatrics.

[14]  ZeGang Ma,et al.  JWH133 inhibits MPP+-induced inflammatory response and iron influx in astrocytes , 2020, Neuroscience Letters.

[15]  Q. Guan A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease , 2019, Journal of immunology research.

[16]  A. Di Paola,et al.  The Endocannabinoid System in Pediatric Inflammatory and Immune Diseases , 2019, International journal of molecular sciences.

[17]  P. Shang,et al.  The Effect of Abnormal Iron Metabolism on Osteoporosis , 2019, Biological Trace Element Research.

[18]  Xiaoxu Yang,et al.  The Role of Transient Receptor Potential Vanilloid 1 in Common Diseases of the Digestive Tract and the Cardiovascular and Respiratory System , 2019, Front. Physiol..

[19]  G. Toro,et al.  Bone alterations in inflammatory bowel diseases , 2019, World journal of clinical cases.

[20]  H. Salem,et al.  A randomized controlled trial evaluating the effects of amlodipine on myocardial iron deposition in pediatric patients with thalassemia major , 2019, Drug design, development and therapy.

[21]  V. Annese A Review of Extraintestinal Manifestations and Complications of Inflammatory Bowel Disease , 2019, Saudi journal of medicine & medical sciences.

[22]  G. A. P. Silva,et al.  Linear growth and bone metabolism in pediatric patients with inflammatory bowel disease. , 2019, Jornal de pediatria.

[23]  I. Yanatori,et al.  DMT1 and iron transport , 2019, Free radical biology & medicine.

[24]  N. Rezaei,et al.  Early onset inflammatory bowel disease: manifestations, genetics and diagnosis. , 2019, The Turkish journal of pediatrics.

[25]  Y. Ginzburg Hepcidin-ferroportin axis in health and disease. , 2019, Vitamins and hormones.

[26]  Peter W. Swaan,et al.  Post‐translational modifications of transporters , 2018, Pharmacology & therapeutics.

[27]  V. Mihál,et al.  Hepcidin in newly diagnosed inflammatory bowel disease in children , 2018, Journal of paediatrics and child health.

[28]  L. Cohen,et al.  Endocrine Late Effects in Childhood Cancer Survivors. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  N. Chattipakorn,et al.  Combined iron chelator and T‐type calcium channel blocker exerts greater efficacy on cardioprotection than monotherapy in iron‐overload thalassemic mice , 2018, European journal of pharmacology.

[30]  E. Miele,et al.  Cannabinoid Receptor 2 Functional Variant Contributes to the Risk for Pediatric Inflammatory Bowel Disease , 2016, Journal of clinical gastroenterology.

[31]  I. Shimon,et al.  Pediatric-onset inflammatory bowel disease poses risk for low bone mineral density at early adulthood. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[32]  B. Cherayil,et al.  Iron and inflammation - the gut reaction. , 2017, Metallomics : integrated biometal science.

[33]  M. Wessling-Resnick,et al.  Regulation of divalent metal transporter-1 by serine phosphorylation , 2016, The Biochemical journal.

[34]  S. Saad,et al.  A randomized trial of amlodipine in addition to standard chelation therapy in patients with thalassemia major. , 2016, Blood.

[35]  D. Girelli,et al.  Serum Hepcidin and Iron Absorption in Paediatric Inflammatory Bowel Disease. , 2016, Journal of Crohn's & colitis.

[36]  W. Hofstetter,et al.  Extracellular Iron is a Modulator of the Differentiation of Osteoclast Lineage Cells , 2015, Calcified Tissue International.

[37]  S. Saeed,et al.  Inflammatory Bowel Disease in Children and Adolescents. , 2021, Advances in pediatrics.

[38]  B. Sands Biomarkers of Inflammation in Inflammatory Bowel Disease. , 2015, Gastroenterology.

[39]  L. French,et al.  Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort , 2015, Inflammatory bowel diseases.

[40]  S. Perrotta,et al.  Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels , 2014, Haematologica.

[41]  G. Veres,et al.  ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory Bowel Disease in Children and Adolescents , 2013, Journal of pediatric gastroenterology and nutrition.

[42]  T. Ganz,et al.  Hepcidin Induction by Pathogens and Pathogen-Derived Molecules Is Strongly Dependent on Interleukin-6 , 2013, Infection and Immunity.

[43]  J. Isaacs,et al.  Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis , 2013, Arthritis Research & Therapy.

[44]  K. Papadakis,et al.  Hepcidin is a key mediator of anemia of inflammation in Crohn's disease. , 2013, Journal of Crohn's & colitis.

[45]  S. Maione,et al.  The 17-β-oestradiol inhibits osteoclast activity by increasing the cannabinoid CB2 receptor expression. , 2013, Pharmacological research.

[46]  F. Locatelli,et al.  Cannabinoid Receptor Type 2 Functional Variant Influences Liver Damage in Children with Non-Alcoholic Fatty Liver Disease , 2012, PloS one.

[47]  A. Fasano,et al.  The cannabinoid receptor type 2 Q63R variant increases the risk of celiac disease: implication for a novel molecular biomarker and future therapeutic intervention. , 2012, Pharmacological research.

[48]  C. Hong,et al.  The bone morphogenetic protein–hepcidin axis as a therapeutic target in inflammatory bowel disease , 2012, Inflammatory bowel diseases.

[49]  S. Perrotta,et al.  The endovanilloid/endocannabinoid system: a new potential target for osteoporosis therapy. , 2011, Bone.

[50]  L. Petrocellis,et al.  The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. , 2009, Bone.

[51]  F. Gonzalez,et al.  Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. , 2009, Cell metabolism.

[52]  A. Zimmer,et al.  Endocannabinoids and the Regulation of Bone Metabolism , 2008, Journal of neuroendocrinology.

[53]  A. Bousvaros,et al.  Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation , 2006, Inflammatory bowel diseases.

[54]  B. Frenkel,et al.  Peripheral cannabinoid receptor, CB2, regulates bone mass. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[55]  N. Khaper,et al.  Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy , 2006, Journal of Molecular Medicine.

[56]  D. Julius,et al.  The capsaicin receptor: a heat-activated ion channel in the pain pathway , 1997, Nature.

[57]  G. Roodman,et al.  Transcriptional regulation of the tartrate-resistant acid phosphatase (TRAP) gene by iron. , 1994, The Biochemical journal.